UNIGE document Scientific Article
previous document  unige:134887  next document
add to browser collection

Conjunctival melanoma targeted therapy: MAPK and PI3K/mTOR pathways inhibition

El Zaoui, Ikram
Bucher, Maya
Rimoldi, Donata
Nicolas, Michael
Pescini Gobert, Rosanna
Bedoni, Nicola
Schalenbourg, Ann
show hidden authors show all authors [1 - 14]
Published in Investigative Ophthalmology & Visual Science. 2019, vol. 60, no. 7, p. 2764-2772
Abstract To analyze the activity of mitogen-activated protein kinase (MAPK) and phosphoinositide 3-kinases/mechanistic target of rapamycin (PI3K/mTOR) pathways in benign and malignant conjunctival melanocytic proliferations and explore whether specific inhibitors can suppress growth of conjunctival melanoma (CJM) cells.
Keywords AdultAged80 and overAntineoplastic Agents/therapeutic useBenzimidazoles/therapeutic useBlottingWesternConjunctival Neoplasms/drug therapy/enzymology/pathologyFemaleFluorescent Antibody TechniqueIndirectHumansImidazoles/therapeutic useIndazoles/therapeutic useMaleMelanoma/drug therapy/enzymology/pathologyMiddle AgedMitogen-Activated Protein Kinases/antagonists & inhibitorsMolecular Targeted TherapyPhosphatidylinositol 3-Kinases/drug effectsProtein Kinase Inhibitors/therapeutic useProto-Oncogene Proteins B-raf/geneticsPyridones/therapeutic usePyrimidinones/therapeutic useQuinolines/therapeutic useSulfonamides/therapeutic useTOR Serine-Threonine Kinases/antagonists & inhibitorsTumor CellsCultured
PMID: 31247083
Full text
Article (Published version) (1.4 MB) - public document Free access
Research group Rôle du CD44 (809)
(ISO format)
EL ZAOUI, Ikram et al. Conjunctival melanoma targeted therapy: MAPK and PI3K/mTOR pathways inhibition. In: Investigative Ophthalmology & Visual Science, 2019, vol. 60, n° 7, p. 2764-2772. doi: 10.1167/iovs.18-26508 https://archive-ouverte.unige.ch/unige:134887

143 hits



Deposited on : 2020-04-22

Export document
Format :
Citation style :